Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphodiesterases in the Central Nervous System: Implications in Mood and Cognitive Disorders
Ying Xu, Han‐Ting Zhang, James M. O’Donnell
Handbook of experimental pharmacology (2011), pp. 447-485
Closed Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
Ana García‐Osta, Mar Cuadrado‐Tejedor, Carolina García, et al.
ACS Chemical Neuroscience (2012) Vol. 3, Iss. 11, pp. 832-844
Open Access | Times Cited: 241
Mouse models of Down syndrome: gene content and consequences
Meenal Gupta, A. Ranjitha Dhanasekaran, Katheleen Gardiner
Mammalian Genome (2016) Vol. 27, Iss. 11-12, pp. 538-555
Open Access | Times Cited: 151
PDE4 as a target for cognition enhancement
Wito Richter, Frank S. Menniti, Han‐Ting Zhang, et al.
Expert Opinion on Therapeutic Targets (2013) Vol. 17, Iss. 9, pp. 1011-1027
Open Access | Times Cited: 130
CREB controls cortical circuit plasticity and functional recovery after stroke
Luca Caracciolo, Máté Marosi, Jose A. Mazzitelli, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 130
Select 3′,5′-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain
Michy P. Kelly, Wendy O. Adamowicz, Susan E. Bove, et al.
Cellular Signalling (2013) Vol. 26, Iss. 2, pp. 383-397
Closed Access | Times Cited: 127
AMPK agonist AICAR improves cognition and motor coordination in young and aged mice
Tali Kobilo, Davide Guerrieri, Yongqing Zhang, et al.
Learning & Memory (2014) Vol. 21, Iss. 2, pp. 119-126
Open Access | Times Cited: 112
The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling
Gang Wang, Ling Chen, Xiaoyu Pan, et al.
Oncotarget (2016) Vol. 7, Iss. 14, pp. 17380-17392
Open Access | Times Cited: 105
1,2,4-Triazolo[1,5-a]pyrimidines in drug design
Killian Oukoloff, Bobby Lucero, Karol R. Francisco, et al.
European Journal of Medicinal Chemistry (2019) Vol. 165, pp. 332-346
Open Access | Times Cited: 94
The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models
Hayley J. MacDonald, Rune Kleppe, Peter D. Szigetvari, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 8
Phosphodiesterase 4 Inhibition in Neuropsychiatric Disorders Associated with Alzheimer’s Disease
Jiming Chen, Zhiyuan Zhu, Fu Xu, et al.
Cells (2025) Vol. 14, Iss. 3, pp. 164-164
Open Access | Times Cited: 1
Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress
Ying Xu, Jianchun Pan, Jiao Sun, et al.
Neurobiology of Aging (2014) Vol. 36, Iss. 2, pp. 955-970
Open Access | Times Cited: 86
PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model
Albert Giralt, Ana Saavedra, Olga Carretón, et al.
Hippocampus (2013) Vol. 23, Iss. 8, pp. 684-695
Closed Access | Times Cited: 82
Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair
Eric P. Knott, Mazen Assi, Sudheendra N.R. Rao, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 4, pp. 696-696
Open Access | Times Cited: 73
Translating concepts of neural repair after stroke: Structural and functional targets for recovery
Robert W. Regenhardt, Hajime Takase, Eng H. Lo, et al.
Restorative Neurology and Neuroscience (2020) Vol. 38, Iss. 1, pp. 67-92
Open Access | Times Cited: 65
Phosphodiesterase 4B: Master Regulator of Brain Signaling
Amy J. Tibbo, George S. Baillie
Cells (2020) Vol. 9, Iss. 5, pp. 1254-1254
Open Access | Times Cited: 54
Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases
Qi Li, Qinghong Liao, Shulei Qi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116386-116386
Closed Access | Times Cited: 6
Regulation of Hippocampal cGMP Levels as a Candidate to Treat Cognitive Deficits in Huntington’s Disease
Ana Saavedra, Albert Giralt, Helena Arumí, et al.
PLoS ONE (2013) Vol. 8, Iss. 9, pp. e73664-e73664
Open Access | Times Cited: 57
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders
Laurent Gomez, Mark E. Massari, Troy Vickers, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 5, pp. 2037-2051
Closed Access | Times Cited: 50
Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery
Michael A. R. Hollas, Manel Ben Aissa, Sue Lee, et al.
Nitric Oxide (2018) Vol. 82, pp. 59-74
Open Access | Times Cited: 47
The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition
Xia Zhu, Wenhua Li, Yongkun Li, et al.
Neuropharmacology (2019) Vol. 153, pp. 20-31
Closed Access | Times Cited: 46
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease
Meiyang Xi, Tian‐Yu Sun, Shejie Chai, et al.
European Journal of Medicinal Chemistry (2022) Vol. 232, pp. 114170-114170
Closed Access | Times Cited: 24
PDE Inhibition and cognition enhancement
Arjan Blokland, Frank S. Menniti, Jos Prickaerts
Expert Opinion on Therapeutic Patents (2012) Vol. 22, Iss. 4, pp. 349-354
Open Access | Times Cited: 52
Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway
Ying Xu, Jianchun Pan, Ling Chen, et al.
The International Journal of Neuropsychopharmacology (2012) Vol. 16, Iss. 4, pp. 835-847
Open Access | Times Cited: 51
Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke
Haitao Wang, Uma Gaur, Jiao Xiao, et al.
International Journal of Biological Sciences (2018) Vol. 14, Iss. 12, pp. 1745-1754
Open Access | Times Cited: 43
In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia
John P. Redrobe, Morten Egevang Jørgensen, Claus T. Christoffersen, et al.
Psychopharmacology (2014) Vol. 231, Iss. 16, pp. 3151-3167
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top